Pharma Industrial India - Professional magazine for pharma industry suppliers and lab technology

Last edition

News about "Relapsed or Refractory Multiple Myeloma"

U.S. Food and Drug Administration Approves Tec-Dara Combination Therapy for Relapsed Multiple Myeloma

U.S. Food and Drug Administration grants rapid approval to Tec-Dara, a combination of teclistamab and daratumumab hyaluronidase-fihj, for adults with relapsed or refractory multiple myeloma after at least one prior therapy.

Relapsed Or Refractory Multiple Myeloma | 07/03/2026 | By News Bureau

FDA Accepts Bristol Myers Squibb's NDA for Iberdomide Combination in Relapsed/Refractory Multiple Myeloma

$FDA Accepts Bristol Myers Squibb's NDA for Iberdomide Combination in Relapsed/Refractory Multiple Myeloma$

Iberdomide, an investigational oral CELMoD therapy, is under FDA review in combination with daratumumab and dexamethasone for patients with relapsed or refractory multiple myeloma.

Relapsed Or Refractory Multiple Myeloma | 19/02/2026 | By News Bureau | 110

Innovent's Tri-Specific Antibody IBI3003 Secures FDA Fast Track Status for Relapsed/Refractory Multiple Myeloma

$Innovent's Tri-Specific Antibody IBI3003 Secures FDA Fast Track Status for Relapsed/Refractory Multiple Myeloma$

Innovent Biologics’ tri-specific antibody IBI3003 has received FDA Fast Track Designation for heavily pretreated relapsed or refractory multiple myeloma, supported by promising early clinical efficacy and safety data.

Relapsed Or Refractory Multiple Myeloma | 27/01/2026 | By News Bureau | 179